Compound interest? US FDA sets up compounding pharmacy advisory committee

By Dan Stanton

- Last updated on GMT

Compounding the problem? US FDA sets up committee for compounding pharmacies
Compounding the problem? US FDA sets up committee for compounding pharmacies
The US FDA has set up a committee to provide advice on scientific, technical and medical issues concerning drug compounding.

After the Drug Quality and Security Act (DQSA) became law last November, the US Food and Drug Administration (FDA) issued guidance​ in which it defined compounding pharmacies as outsourcing facilities in order to ensure such firms comply with current Good Manufacturing Practices (cGMP).

Yesterday the agency announced it had selected a committee of 12 voting and two non-voting members - comprising experts in pharmaceutical compounding and manufacturing, pharmacy, medicine, and pharmaceutical regulation​ - taken from over 100 nominations.

“This is a key step toward implementing the compounding provisions of the Drug Quality and Security Act,”​ director of the FDA’s Center for Drug Evaluation and Research Janet Woodcock said, adding compounders and the agency “will benefit greatly from the advice and recommendations the members of the committee provide.”

One area the Committee will advise on is Section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) added earlier this year​ which lays out specifics on facility design, environmental and personnel monitoring, equipment, production and process controls, release testing, lab controls and other areas of concern.

The need to address compounders on quality issues came to light after an outbreak of fungal meningitis which affected 751 patients and killed 64 in 2012 was traced back to medication packaged and marketed by the New England Compounding Center (NECC), a compounding pharmacy in Framingham, Massachusetts.

Glenn Chin, a supervising pharmacist at the company, was arrested by US authorities in September​ as part of an ongoing investigation.

Related news

Show more

Related products

show more

Ultra Low Temperature Packaging solutions

Ultra Low Temperature Packaging solutions

Content provided by Almac Group | 12-Feb-2024 | Case Study

Advanced Therapy Medicinal Products (ATMPs) offer ground-breaking opportunities for treating injuries and disease, in particular for cases of severe, untreatable...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Follow us

Products

View more

Webinars